Sitagliptin
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.
Medicare announces price cuts for 10 drugs in first round of drug price negotiations
The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.
Semaglutide does not raise risk for neurologic disorders for adults with type 2 diabetes
Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.
GRADE: Insulin glargine, liraglutide better maintain glycemic control than other agents
Insulin glargine and the GLP-1 receptor agonist liraglutide are more effective at achieving an HbA1c of less than 7% than the sulfonylurea glimepiride or the DPP-IV inhibitor sitagliptin, according to data from the GRADE trial.
Top in endocrinology: Contaminated sitagliptin; added benefits of bariatric surgery
Although some samples of the antidiabetic drug sitagliptin may contain a human carcinogen called NTTP, the FDA said it hopes to avoid a shortage of the medication by temporarily allowing its distribution.
FDA: Possibly contaminated sitagliptin may be distributed to avoid shortage
The FDA announced it has learned that some samples of sitagliptin, used to treat type 2 diabetes, may contain a “nitrosamine impurity,” Nitroso-STG-19 or NTTP, which may be a human carcinogen.
GRADE: GLP-1 agonists, insulin more effective than other diabetes drugs
In a head-to-head study of four classes of glucose-lowering drugs, the GLP-1 receptor agonist liraglutide and insulin glargine were more effective for maintaining HbA1c below 7% than a sulfonylurea or DPP-IV inhibitor.
Sitagliptin may prevent acute GVHD after peripheral blood stem cell transplantation
Sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative allogeneic peripheral blood stem cell transplantation, according to phase 2 study results published in The New England Journal of Medicine.
Higher dose of sitagliptin does not increase risk for congestive heart failure in CKD
Researchers from Canada observed no link between higher doses of sitagliptin and increased risk for congestive heart failure in a cohort of patients older than 66 years who had both type 2 diabetes and chronic kidney disease.
Sitagliptin linked to lower mortality rate in adults with type 2 diabetes, COVID-19
Adults with type 2 diabetes who were hospitalized with COVID-19 in northern Italy had a lower mortality rate and better health outcomes when treated with the DPP-IV inhibitor sitagliptin, according to study data published in Diabetes Care.